{"id":"W2791290180","doi":"10.1016/s1470-2045(18)30144-x","title":"Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study","year":2018,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":576,"is_retracted":false,"has_abstract":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"National Cancer Institute; Kite Pharma; EMD Serono; MacroGenics; Sanofi; GlaxoSmithKline; Amgen; Pfizer; Genentech; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Durvalumab; Medicine; Internal medicine; Oncology; Lung cancer; Anaplastic lymphoma kinase; Response Evaluation Criteria in Solid Tumors; Cohort; Progressive disease; Cancer; Nivolumab; Anaplastic large-cell lymphoma; Immunotherapy; Chemotherapy; Lymphoma; Malignant pleural effusion","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007114909,0.0003166586,0.0009313436,0.00006213387,0.0002930119,0.00005500825,0.0005194657,0.0001450491,0.0008080586],"category_scores_gemma":[0.00003266413,0.0001743301,0.00006400422,0.0002027057,0.0002032467,0.0001134714,0.0001104882,0.0001541137,0.00003116904],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000631496,"about_ca_system_score_gemma":0.0006696901,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001352887,"about_ca_topic_score_gemma":0.006361111,"domain_scores_codex":[0.9980721,0.0002133902,0.0004400912,0.0005207222,0.0001526007,0.0006010415],"domain_scores_gemma":[0.998441,0.000220108,0.0002388455,0.0007874049,0.0001882564,0.0001243225],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","study_design_scores_codex":[0.3943121,0.05721429,0.005688755,0.0002345421,0.002469524,0.0003394756,0.01469214,0.000008419827,0.3089917,0.00003332619,0.01924395,0.1967718],"study_design_scores_gemma":[0.3101373,0.3131844,0.001618038,0.0001895102,0.001669925,0.000175294,0.002101048,0.001485274,0.0501548,0.00007127991,0.318612,0.00060108],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9843174,0.0005144307,0.00008992344,0.005767821,0.0009343648,0.005087559,0.0000612681,0.00008652246,0.003140707],"genre_scores_gemma":[0.9801368,0.0006400453,0.001796787,0.006013251,0.002109719,0.001342557,0.0000710707,0.00007026906,0.007819506],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2993681,"threshold_uncertainty_score":0.8847675,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1328551074004894,"score_gpt":0.452357169030372,"score_spread":0.3195020616298826,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}